Clinical Trial Update: Oxtellar Extended Release (Oxcarbazepine Extended Release) Patients With Trigeminal Neuralgia [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating Oxtellar Extended Release (oxcarbazepine extended release) for trigeminal neuralgia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Trigeminal Neuralgia

Drugs mentioned

• Oxtellar Extended Release (oxcarbazepine extended release)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Trigeminal Neuralgia | Phase 4 | Status: WITHDRAWN